FITXR
23.3.2023 14:01:34 CET | Business Wire | Press release
FitXR is continuing to expand its popular virtual reality (VR) fitness offering with the UK, EU and Asia markets by launching on the popular PICO VR headsets. FitXR’s launch on PICO represents its commitment to make VR fitness accessible to all, irrespective of the user’s preference in hardware choice. As the mass market appeal in VR continues to grow, it will bring with it increased interest in hardware developers, innovation and consumer choice and in turn the desirability in multi-platform offerings like FitXR.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005314/en/
(Photo: Business Wire)
In January 2023, FitXR launched two new studio offerings: Sculpt and Combat, to add to its already robust suite of offerings that include High Intensity Interval Training (HIIT), Dance and Box workout options. The launch of Sculpt (workouts inspired by barre, pilates, and isometric strength training) and Combat (workouts inspired by karate, muay thai and taekwondo) support FitXR’s continued mission to provide the widest variety of workout experiences available in the metaverse today.
FitXR is now reaching new audiences by bringing its at-home virtual fitness experience to PICO headsets. Starting today, any consumer who downloads FitXR onto their PICO 4 or PICO Neo Link 3 headset will get 30 days free membership; an offer running until the 30th of April.
“Launching on PICO is a pivotal moment for FitXR,” said Sam Cole, CEO and Co-founder of FitXR. “We already offer the most diverse and unique fitness experience, and by expanding to the new PICO headset, we’re furthering our aim to provide this to every person, in every household, in every geography, and on any hardware device. It also reinforces our position as the leading global VR Fitness app with members around the world.”
“For PICO, launching FitXR as a subscription app on our platform underlines our commitment to bring the widest variety of high quality and customizable fitness experiences to our customers,” said Peter Li, Head of Gaming Partnerships at PICO.
FitXR’s launch on PICO is also indicative of the heightened appetite for combining technology and gaming to provide the optimal fitness experience. On FitXR, users can access different fitness studios whilst customising these experiences to meet their goals. Every time members enter the app, they can choose exactly how they want to work out; by studio type, music genre, intensity level, and/or time duration and then choose from one of many fully immersive 3D workout environments. Members can Dance or Box on a downtown city building rooftop, take Sculpt classes on the beachfront seaside or fight and defend in an outdoor martial arts-inspired Combat arena - all while punching flying fireballs, earning points and extending their winning streak.
“We never forget to bring the fun. The fun matters just as much as the results,” said Lisa Raggiri, Chief Marketing Officer at FitXR. “Whilst all of our classes are choreographed by certified fitness instructors to ensure results, we are strong believers in leveraging the unique immersive nature of VR to provide a fun escape. We know that by jumping into a fully immersive workout, our members have greater enjoyment, improve their consistency and see real results.”
In case variety, customization, gamification and numerous 3D environments wasn’t enough, FitXR is launching its first Box Training Program created in partnership with Olympic Boxing Champion Nicola Adams.
Says Nicola: “I am so excited to be able to finally share that I’ve been working closely alongside FitXR on this new boxing starter program, Box Like a Pro. We’ve broken it down and will delve into the principles of boxing – whether you’re looking to work on the perfect stance or refining your uppercut, this program is one for all. Regardless of your level, this program provides both beginners and intermediate boxers with the foundations and technical skills to build on and succeed. Having begun boxing at a young age, it’s been vital in helping build up my confidence and I hope users step away from this program feeling stronger and more energized, both mentally and physically. My hope is that I can inspire people to get more active, build and maintain a healthy lifestyle and show that fitness can be fun! I love spending weekends gaming, so I’ve enjoyed being able to blend it into fitness with FitXR. It’s been inspiring to partner with FitXR who have made transformative strides in elevating fitness for the better and making it more inclusive for all.”
About FitXR:
FitXR merges immersive VR with total body workouts designed by top fitness experts. Dedicated to making fitness more fun and accessible for everyone, FitXR offers classes within five distinct workout studios - Box, Dance, HIIT, Sculpt and Combat. FitXR provides a truly engaging, multiplayer experience along with constantly refreshed classes, environments and music. FitXR is available on Meta Quest 2.
About PICO:
Founded in March 2015, PICO is a leading VR company with independent innovation and R&D capabilities, focusing on VR all-in-one technology. Embracing a mission to bridge connections, enrich life, and release infinity, PICO is committed to building an integrated XR platform that inspires the community and empowers developers, creators, and businesses. To learn more, visit picoxr.com or business.picoxr.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005314/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
